HWM
BIO icon

Hemington Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hemington Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$8K Buy
29
+4
+16% +$1.09K ﹤0.01% 953
2025
Q2 		$6K Buy
25
+16
+178% +$3.78K ﹤0.01% 1023
2025
Q1 		$2K Sell
9
-2
-18% -$602 ﹤0.01% 1261
2024
Q4 		$3K Buy
11
+2
+22% +$679 ﹤0.01% 1143
2024
Q3 		$3K Buy
+9
New +$2.86K ﹤0.01% 1052

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Hemington Wealth Management's BIO Position: Q3 2025 in Review

Hemington Wealth Management increased its Bio-Rad Laboratories Class A (BIO) stake by 16% in Q3 2025, buying an estimated $1.09K and bringing the position to 29 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

Hemington Wealth Management first reported a position in BIO in Q3 2024 and has held it in 5 quarters since. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

  • Hemington Wealth Management held 29 shares of Bio-Rad Laboratories Class A worth $8K as of Q3 2025.
  • Hemington Wealth Management bought 4 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $1.09K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #953 holding.
  • Hemington Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and has held it in 5 quarters since.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.